JOHNSON & JOHNSON(JNJ)— Stock Profile, AI Score & Financials

Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-28.

JOHNSON & JOHNSON (JNJ) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JNJ at 69.0/100 on a 32-signal composite quality model, placing it at rank #285 of 2,961 stocks — the top 10% of the AI-ranked universe. JNJ scores in the top quartile across revenue scale (98.7), balance sheet strength (86.8), profitability (76.7). Shareholder dilution risk is elevated at 47.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), JOHNSON & JOHNSON reports quarterly revenue of $25.3B, net income of $5.5B, an operating margin of 26.7%. Top institutional holders of JNJ by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. JNJ trades on the NYSE exchange and files with the SEC under CIK 200406. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JNJ daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for JOHNSON & JOHNSON directly from SEC EDGAR.